SVB Leerink Increases Agilent Technologies (NYSE:A) Price Target to $160.00

Agilent Technologies (NYSE:AGet Rating) had its price objective hoisted by stock analysts at SVB Leerink from $145.00 to $160.00 in a research report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has an “outperform” rating on the medical research company’s stock. SVB Leerink’s target price would indicate a potential upside of 10.24% from the company’s current price.

A number of other analysts have also issued reports on A. KeyCorp lifted their price target on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Tuesday. Bank of America lifted their price objective on Agilent Technologies from $148.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, August 17th. Wells Fargo & Company lifted their price objective on Agilent Technologies from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 17th. Evercore ISI lifted their price objective on Agilent Technologies to $145.00 in a research report on Monday, August 22nd. Finally, Cowen lifted their price objective on Agilent Technologies to $160.00 in a research report on Monday, August 22nd. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $153.23.

Agilent Technologies Stock Performance

Shares of NYSE:A opened at $145.14 on Tuesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.94 and a quick ratio of 1.41. The business’s 50 day moving average price is $133.08 and its 200-day moving average price is $128.04. The firm has a market capitalization of $42.97 billion, a PE ratio of 33.06, a P/E/G ratio of 2.67 and a beta of 1.06. Agilent Technologies has a 1 year low of $112.52 and a 1 year high of $165.68.

Agilent Technologies (NYSE:AGet Rating) last issued its quarterly earnings results on Monday, November 21st. The medical research company reported $1.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.14. The firm had revenue of $1.85 billion for the quarter, compared to analyst estimates of $1.76 billion. Agilent Technologies had a return on equity of 28.46% and a net margin of 19.94%. The business’s revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.21 earnings per share. As a group, equities research analysts expect that Agilent Technologies will post 5.07 earnings per share for the current fiscal year.

Insider Activity

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 6,775 shares of the company’s stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $148.19, for a total transaction of $1,003,987.25. Following the completion of the sale, the chief executive officer now directly owns 270,896 shares of the company’s stock, valued at approximately $40,144,078.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Michael R. Mcmullen sold 6,775 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $148.19, for a total transaction of $1,003,987.25. Following the completion of the transaction, the chief executive officer now directly owns 270,896 shares of the company’s stock, valued at approximately $40,144,078.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Padraig Mcdonnell sold 2,103 shares of the company’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $122.89, for a total value of $258,437.67. Following the completion of the sale, the vice president now owns 13,217 shares in the company, valued at approximately $1,624,237.13. The disclosure for this sale can be found here. In the last three months, insiders sold 35,309 shares of company stock valued at $4,846,147.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bromfield Sneider Wealth Advisors acquired a new stake in Agilent Technologies during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC grew its holdings in Agilent Technologies by 34.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 298 shares of the medical research company’s stock valued at $37,000 after buying an additional 77 shares during the last quarter. Edge Capital Group LLC grew its holdings in Agilent Technologies by 53.0% during the 3rd quarter. Edge Capital Group LLC now owns 303 shares of the medical research company’s stock valued at $37,000 after buying an additional 105 shares during the last quarter. Guardian Wealth Advisors LLC acquired a new stake in Agilent Technologies during the 3rd quarter valued at $42,000. Finally, J.W. Cole Advisors Inc. grew its holdings in Agilent Technologies by 7,201.6% during the 1st quarter. J.W. Cole Advisors Inc. now owns 124,493 shares of the medical research company’s stock valued at $45,000 after buying an additional 122,788 shares during the last quarter.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Read More

Stock Target Advisor logo

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.